Eptifibatide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Eptifibatide and local guidelines before prescribing.
Glycoprotein IIb/IIIa inhibitor
Mechanism
Glycoprotein IIb/IIIa inhibitor.
Uses
Acute coronary syndrome, PCI.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Bleeding, thrombocytopenia.
Interactions
Anticoagulants and antiplatelets.
Contraindications and cautions
Active bleeding, severe hypertension
Monitoring
Platelets, bleeding
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose if CrCl below 50
Overdose and reversal
Platelet transfusion
Special advice
Used in high-risk NSTEMI before PCI.
More from the textbook: uses, cautions and other points
- GPIIb/IIIa inhibitors (tirofiban, eptifibatide) - IV, used in the cath lab for large clot burden.
Cardiology: Anatomy Physiology and Pharmacology - GPIIb/IIIa inhibitors (tirofiban, eptifibatide) and IV cangrelor - specialist use in coronary intervention; bleeding and thrombocytopenia.
Haematology: Anatomy Physiology and Pharmacology - Aggregation - GPIIb/IIIa receptors bind fibrinogen and link platelets together (blocked by tirofiban and eptifibatide).
Haematology: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)